Bristol Myers Squibb announces the continuation of the ADEPT-2 Phase 3 study for psychosis associated with Alzheimer’s Disease. The study aims to evaluate the safety and efficacy of Cobenfy, a potential treatment for hallucinations and delusions in Alzheimer’s patients. After a review, the Data Monitoring Committee recommended enrolling more patients to ensure rigorous standards. BMS remains committed to finding innovative treatments for this unmet medical need.
The ADEPT-2 study focuses on the Neuropsychiatric Inventory-Clinician (NPI-C) and Clinical Global Impression-Severity (CGI-S) as primary endpoints. BMS, a global biopharmaceutical company, is dedicated to developing novel approaches to treat Alzheimer’s Disease and its symptoms.
BristolMyersSquibb #ADEPT2 #AlzheimersResearch #Cobenfy #PsychosisTreatment
source